

Lieping Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5662259/publications.pdf>

Version: 2024-02-01

287
papers

74,409
citations

997

114
h-index

529

266
g-index

336
all docs

336
docs citations

336
times ranked

56515
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti-“PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	27.0	10,727
2	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
3	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 2002, 8, 793-800.	30.7	4,217
4	Phase I Study of Single-Agent Anti-“Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology, 2010, 28, 3167-3175.	1.6	2,667
5	Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology, 2013, 13, 227-242.	22.7	2,382
6	B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine, 1999, 5, 1365-1369.	30.7	2,200
7	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-“PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	7.0	2,050
8	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	12.4	1,844
9	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	12.4	1,837
10	Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 2008, 8, 467-477.	22.7	1,399
11	Blockade of B7-H1 improves myeloid dendritic cell-“mediated antitumor immunity. Nature Medicine, 2003, 9, 562-567.	30.7	1,157
12	Anti-“PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391.	8.2	1,112
13	Co-inhibitory molecules of the B7-“CD28 family in the control of T-cell immunity. Nature Reviews Immunology, 2004, 4, 336-347.	22.7	1,110
14	Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 1992, 71, 1093-1102.	28.9	1,042
15	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 2018, 175, 313-326.	28.9	985
16	B7-H3: A costimulatory molecule for T cell activation and IFN-Î³ production. Nature Immunology, 2001, 2, 269-274.	14.5	856
17	Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Medicine, 1997, 3, 682-685.	30.7	830
18	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	12.8	780

#	ARTICLE	IF	CITATIONS
19	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17174-17179.	7.1	723
20	Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation, 2014, 94, 107-116.	3.7	697
21	Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research, 2005, 65, 1089-96.	0.9	687
22	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research, 2013, 73, 1733-1741.	0.9	678
23	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine, 2006, 203, 871-881.	8.5	638
24	B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity. Immunity, 2003, 18, 849-861.	14.3	623
25	PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nature Immunology, 2010, 11, 535-542.	14.5	583
26	Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews Cancer, 2007, 7, 95-106.	28.4	564
27	Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell, 2019, 176, 334-347.e12.	28.9	553
28	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clinical Cancer Research, 2013, 19, 462-468.	7.0	485
29	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 2019, 25, 656-666.	30.7	461
30	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clinical Cancer Research, 2013, 19, 1021-1034.	7.0	458
31	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 2019, 25, 4592-4602.	7.0	447
32	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008, 111, 3635-3643.	1.4	438
33	B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Research, 2003, 63, 6501-5.	0.9	401
34	Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN- γ -induced upregulation of B7-H1 (CD274). FEBS Letters, 2006, 580, 755-762.	2.8	394
35	LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response. Journal of Immunology, 2000, 164, 4105-4110.	0.8	355
36	B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes. Immunity, 2004, 20, 327-336.	14.3	352

#	ARTICLE	IF	CITATIONS
37	NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies. Cellular Immunology, 1998, 190, 167-172.	3.0	335
38	Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. Immunity, 2004, 20, 337-347.	14.3	331
39	Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions. Cancer Research, 2009, 69, 8067-8075.	0.9	331
40	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	1.2	326
41	Costimulation of T cells for tumor immunity. Trends in Immunology, 1993, 14, 483-486.	7.5	313
42	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response. Clinical Cancer Research, 2013, 19, 5542-5542.	7.0	313
43	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 2003, 63, 7462-7.	0.9	312
44	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. Cancer Research, 2007, 67, 8900-8905.	0.9	294
45	Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nature Medicine, 2000, 6, 283-289.	30.7	293
46	53BP1 is required for class switch recombination. Journal of Cell Biology, 2004, 165, 459-464.	5.2	292
47	B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood, 2010, 116, 1291-1298.	1.4	287
48	Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. Journal of Clinical Investigation, 2008, 118, 376-386.	8.2	277
49	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 2019, 20, 835-851.	14.5	277
50	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. Journal of Experimental Medicine, 2003, 197, 1083-1091.	8.5	259
51	Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood, 2009, 114, 3101-3112.	1.4	256
52	Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood, 2012, 120, 4772-4782.	1.4	256
53	Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells. Journal of Immunology, 2006, 177, 40-44.	0.8	252
54	B7-H1 pathway and its role in the evasion of tumor immunity. Journal of Molecular Medicine, 2003, 81, 281-287.	3.9	249

#	ARTICLE	IF	CITATIONS
55	Interferon- γ enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 155, 172-182.	2.3	249
56	Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. <i>Hepatology</i> , 2008, 47, 296-305.	7.3	242
57	Costimulation of α T cells by B7-H2, a B7-like molecule that binds ICOS. <i>Blood</i> , 2000, 96, 2808-2813.	1.4	236
58	Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family. <i>Journal of Immunology</i> , 2003, 171, 4650-4654.	0.8	233
59	Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 6341-6347.	7.0	230
60	Advances in targeting cell surface signalling molecules for immune modulation. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 130-146.	46.4	229
61	Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. <i>Journal of Clinical Investigation</i> , 2014, 124, 1966-1975.	8.2	227
62	Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells. <i>Journal of Immunology</i> , 2002, 168, 4262-4267.	0.8	216
63	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 4663-4673.	7.0	210
64	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. <i>Blood</i> , 2007, 110, 180-185.	1.4	209
65	The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. <i>Journal of Clinical Investigation</i> , 2001, 108, 1771-1780.	8.2	204
66	Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. <i>Journal of Clinical Investigation</i> , 2002, 109, 651-659.	8.2	203
67	Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. <i>Journal of Clinical Investigation</i> , 2012, 122, 1066-1075.	8.2	202
68	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. <i>Blood</i> , 2001, 97, 1809-1816.	1.4	201
69	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	7.0	198
70	Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models. <i>Journal of Immunology</i> , 2011, 187, 1537-1541.	0.8	196
71	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. <i>Blood</i> , 2011, 117, 2423-2432.	1.4	195
72	Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. <i>European Journal of Immunology</i> , 1998, 28, 1116-1121.	2.9	194

#	ARTICLE	IF	CITATIONS
73	Cigarette Smoke Extract Suppresses Human Dendritic Cell Function Leading to Preferential Induction of Th-2 Priming. <i>Journal of Immunology</i> , 2005, 175, 2684-2691.	0.8	192
74	B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1. <i>Biology of Reproduction</i> , 2003, 68, 1496-1504.	2.7	189
75	CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice. <i>Circulation</i> , 2008, 117, 1292-1301.	1.6	188
76	Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy. <i>Journal of Experimental Medicine</i> , 1997, 186, 229-238.	8.5	185
77	Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2002, 168, 1457-1465.	0.8	184
78	Differential binding properties of B7-H1 and B7-DC to programmed death-1. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 672-677.	2.1	181
79	PD-1 on dendritic cells impedes innate immunity against bacterial infection. <i>Blood</i> , 2009, 113, 5811-5818.	1.4	179
80	Interferon- β and tumor necrosis factor- α induce an immunoinhibitory molecule, B7-H1, via nuclear factor- κ B activation in blasts in myelodysplastic syndromes. <i>Blood</i> , 2010, 116, 1124-1131.	1.4	179
81	The New B7s: Playing a Pivotal Role in Tumor Immunity. <i>Journal of Immunotherapy</i> , 2007, 30, 251-260.	2.4	178
82	Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. <i>Journal of Neuroinflammation</i> , 2008, 5, 48.	7.2	174
83	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. <i>Nature Medicine</i> , 2002, 8, 1405-1413.	30.7	171
84	PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells. <i>Journal of Immunology</i> , 2015, 194, 5801-5811.	0.8	170
85	Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. <i>Blood</i> , 2007, 110, 186-192.	1.4	169
86	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. <i>Cancer</i> , 2005, 104, 2084-2091.	4.1	166
87	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	8.2	164
88	Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation. <i>Journal of Immunology</i> , 2003, 171, 4156-4163.	0.8	163
89	B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells. <i>Journal of Immunology</i> , 2004, 173, 5445-5450.	0.8	163
90	Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity. <i>Journal of Immunology</i> , 2002, 169, 4230-4236.	0.8	162

#	ARTICLE	IF	CITATIONS
91	Cytokine-Mediated Disruption of Lymphocyte Trafficking, Hemopoiesis, and Induction of Lymphopenia, Anemia, and Thrombocytopenia in Anti-CD137-Treated Mice. <i>Journal of Immunology</i> , 2007, 178, 4194-4213.	0.8	162
92	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. <i>Blood</i> , 2003, 101, 2514-2520.	1.4	157
93	Fine tuning the immune response through B7-3 and B7-4. <i>Immunological Reviews</i> , 2009, 229, 145-151.	6.0	155
94	Targeting CD137 enhances the efficacy of cetuximab. <i>Journal of Clinical Investigation</i> , 2014, 124, 2668-2682.	8.2	154
95	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	6.8	153
96	Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model. <i>Immunity</i> , 2011, 34, 466-478.	14.3	152
97	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005, 25, 2537-2546.	3.6	150
98	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 370-378.	7.0	150
99	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	7.0	150
100	B7-H5 costimulates human T cells via CD28H. <i>Nature Communications</i> , 2013, 4, 2043.	12.8	148
101	Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. <i>Journal of Clinical Investigation</i> , 2004, 113, 694-700.	8.2	146
102	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. <i>Journal of Experimental Medicine</i> , 2003, 198, 31-38.	8.5	144
103	In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. <i>Journal of Experimental Medicine</i> , 2005, 201, 1531-1541.	8.5	140
104	Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. <i>Journal of Clinical Investigation</i> , 2002, 109, 651-659.	8.2	138
105	Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. <i>JAMA Oncology</i> , 2016, 2, 1403.	7.1	135
106	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	46.4	134
107	B7-H2 Is a Costimulatory Ligand for CD28 in Human. <i>Immunity</i> , 2011, 34, 729-740.	14.3	133
108	Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. <i>Cancer Journal (Sudbury, Mass.)</i> , 2014, 20, 256-261.	2.0	131

#	ARTICLE	IF	CITATIONS
109	Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2005, 33, 280-289.	2.9	129
110	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. <i>Cancer Research</i> , 2006, 66, 2442-2450.	0.9	129
111	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2022, 40, 45-74.	21.8	122
112	Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. <i>Blood</i> , 2009, 114, 3431-3438.	1.4	121
113	B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. <i>Journal of Immunology</i> , 2010, 185, 2747-2753.	0.8	120
114	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncotmunology</i> , 2015, 4, e998538.	4.6	119
115	B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B. <i>Journal of Immunology</i> , 2007, 178, 6634-6641.	0.8	118
116	Blockade of B7-H1 (Programmed Death Ligand 1) Enhances Humoral Immunity by Positively Regulating the Generation of T Follicular Helper Cells. <i>Journal of Immunology</i> , 2011, 186, 5648-5655.	0.8	118
117	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	7.0	117
118	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. <i>Microbes and Infection</i> , 2004, 6, 759-766.	1.9	112
119	Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 5708-5717.	7.0	111
120	Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. <i>Cancer Research</i> , 2002, 62, 1884-9.	0.9	108
121	Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1223-1233.	4.2	107
122	DKK2 imparts tumor immunity evasion through β^2 -catenin-independent suppression of cytotoxic immune-cell activation. <i>Nature Medicine</i> , 2018, 24, 262-270.	30.7	106
123	Ligation of CD137 receptor prevents and reverses established anergy of CD8 ⁺ cytolytic T lymphocytes in vivo. <i>Blood</i> , 2004, 103, 177-184.	1.4	105
124	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. <i>European Journal of Immunology</i> , 2008, 38, 2706-2717.	2.9	103
125	Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8 ⁺ T cells. <i>Cancer Research</i> , 2002, 62, 3459-65.	0.9	101
126	Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 6929-6935.	0.8	100

#	ARTICLE	IF	CITATIONS
127	Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse Model. Journal of the National Cancer Institute, 2000, 92, 931-936.	6.3	98
128	Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale Journal of Biology and Medicine, 2011, 84, 409-21.	0.2	97
129	Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 1393-1398.	8.5	96
130	Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB Journal, 2003, 17, 1-16.	0.5	95
131	Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head and Neck, 2001, 23, 899-906.	2.0	92
132	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7551-7556.	7.1	92
133	B7-H3 promotes acute and chronic allograft rejection. European Journal of Immunology, 2005, 35, 428-438.	2.9	91
134	PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine, 2019, 11, .	12.4	90
135	Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis. Journal of Immunology, 2008, 180, 7506-7515.	0.8	89
136	Cutting Edge: Selective Impairment of CD8+ T Cell Function in Mice Lacking the TNF Superfamily Member LIGHT. Journal of Immunology, 2002, 168, 4832-4835.	0.8	88
137	Immunological ignorance of silent antigens as an explanation of tumor evasion. Trends in Immunology, 1998, 19, 27-30.	7.5	86
138	A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery, 2021, 11, 1700-1715.	9.4	86
139	Cutting Edge: IFN- γ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development. Journal of Immunology, 2008, 181, 5842-5846.	0.8	83
140	Rejection of Disseminated Metastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 4-1BB Costimulation. Molecular Therapy, 2000, 2, 39-46.	8.2	81
141	Can Co-stimulated Tumor Immunity be Therapeutically Efficacious?. Immunological Reviews, 1995, 145, 123-145.	6.0	80
142	CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood, 2007, 109, 4882-4889.	1.4	77
143	IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends in Immunology, 2001, 22, 113-115.	6.8	73
144	B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. European Journal of Immunology, 2008, 38, 1734-1744.	2.9	72

#	ARTICLE	IF	CITATIONS
145	B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. <i>Blood</i> , 2009, 113, 1759-1767.	1.4	72
146	In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. <i>Blood</i> , 2000, 95, 2346-2351.	1.4	70
147	Target-Dependent B7-H1 Regulation Contributes to Clearance of Central Nervous System Infection and Dampens Morbidity. <i>Journal of Immunology</i> , 2009, 182, 5430-5438.	0.8	70
148	Mechanistic Assessment of PD-1/CD137 Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens. <i>Journal of Immunology</i> , 2015, 194, 5294-5304.	0.8	68
149	Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 549-557.	8.2	68
150	B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2741-2746.	7.1	67
151	Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2014, 193, 2565-2573.	0.8	67
152	Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. <i>Blood</i> , 2007, 109, 4097-4104.	1.4	66
153	Tumor-Induced Immune Suppression of <i>In vivo</i> Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor β. <i>Cancer Research</i> , 2008, 68, 5432-5438.	0.9	66
154	Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 1830-1838.	0.8	65
155	Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. <i>International Journal of Cancer</i> , 2004, 110, 51-60.	5.1	65
156	Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data. <i>PLoS Medicine</i> , 2009, 6, e1000166.	8.4	65
157	B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. <i>European Journal of Immunology</i> , 2010, 40, 3117-3127.	2.9	65
158	Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. <i>Blood</i> , 2010, 116, 2266-2276.	1.4	64
159	Ex Vivo Expanded Hematopoietic Stem Cells Overcome the MHC Barrier in Allogeneic Transplantation. <i>Cell Stem Cell</i> , 2011, 9, 119-130.	11.1	63
160	PD-1 as an Immune Modulatory Receptor. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 262-264.	2.0	62
161	Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. <i>Journal of Clinical Investigation</i> , 2006, 116, 1045-1051.	8.2	62
162	Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity. <i>Cancer Research</i> , 2004, 64, 4965-4972.	0.9	61

#	ARTICLE	IF	CITATIONS
163	B7H1/CD80 Interaction Augments PD-1-Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 194, 560-574.	0.8	61
164	Progressive Depletion of Peripheral B Lymphocytes in 4-1BB (CD137) Ligand/IL-15-Transgenic Mice. <i>Journal of Immunology</i> , 2001, 167, 2671-2676.	0.8	60
165	RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF- κ B. <i>Blood</i> , 2001, 97, 2702-2707.	1.4	59
166	CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. <i>Cellular Immunology</i> , 2003, 226, 20-29.	3.0	59
167	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. <i>Nature Medicine</i> , 2002, 8, 1405-1413.	30.7	58
168	PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. <i>PLoS Pathogens</i> , 2015, 11, e1005224.	4.7	58
169	A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis. <i>Nature Communications</i> , 2016, 7, 10339.	12.8	57
170	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2856.	3.0	55
171	Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
172	Host APCs Augment In Vivo Expansion of Donor Natural Regulatory T Cells via B7H1/B7.1 in Allogeneic Recipients. <i>Journal of Immunology</i> , 2011, 186, 2739-2749.	0.8	53
173	Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. <i>Cell Reports</i> , 2014, 6, 625-632.	6.4	53
174	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1046-1060.	1.1	52
175	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. <i>Nature Communications</i> , 2021, 12, 951.	12.8	50
176	Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege. <i>Journal of Investigative Dermatology</i> , 2014, 134, 736-745.	0.7	49
177	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. <i>Oncotarget</i> , 2015, 6, 24990-25002.	1.8	49
178	CD137-Mediated Pathogenesis from Chronic Hepatitis to Hepatocellular Carcinoma in Hepatitis B Virus-Transgenic Mice. <i>Journal of Immunology</i> , 2010, 185, 7654-7662.	0.8	48
179	The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. <i>Experimental Hematology</i> , 2006, 34, 888-894.	0.4	47
180	Blockade of endogenous B7-H1 suppresses antibacterial protection after primary <i>Listeria monocytogenes</i> infection. <i>Immunology</i> , 2008, 123, 90-99.	4.4	47

#	ARTICLE	IF	CITATIONS
181	Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4. <i>Nature Communications</i> , 2018, 9, 742.	12.8	47
182	CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. <i>Blood</i> , 2010, 115, 1941-1948.	1.4	45
183	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. <i>Kidney International</i> , 2005, 68, 2091-2102.	5.2	44
184	Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. <i>Journal of Leukocyte Biology</i> , 2008, 83, 755-764.	3.3	44
185	Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 245-267.	1.1	44
186	Expression of the Costimulatory Molecule B7-H2 (Inducible Costimulator Ligand) by Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 28, 563-573.	2.9	42
187	Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. <i>Life Sciences</i> , 1997, 60, 2035-2041.	4.3	41
188	Suppression of Human T-Cell Responses to \hat{I}^2 -Cells by Activation of B7-H4 Pathway. <i>Cell Transplantation</i> , 2006, 15, 399-410.	2.5	41
189	Modulation of the Immune Response Through 4-1BB. <i>Advances in Experimental Medicine and Biology</i> , 2002, 465, 355-362.	1.6	40
190	B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets. <i>PLoS ONE</i> , 2015, 10, e0130126.	2.5	40
191	Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM. <i>Science Advances</i> , 2016, 2, e1500637.	10.3	37
192	Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma. <i>Journal of Immunotherapy</i> , 2000, 23, 430-437.	2.4	36
193	B7-H1 on Hepatocytes Facilitates Priming of Specific CD8 T Cells But Limits the Specific Recall of Primed Responses. <i>Gastroenterology</i> , 2008, 135, 980-988.	1.3	36
194	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. <i>Cancer</i> , 2003, 97, 2203-2211.	4.1	35
195	B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). <i>FEBS Letters</i> , 2005, 579, 6259-6264.	2.8	35
196	B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3126-3131.	7.1	35
197	A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. <i>Cellular and Molecular Immunology</i> , 2018, 15, 838-845.	10.5	35
198	The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection. <i>Frontiers in Immunology</i> , 2019, 10, 54.	4.8	35

#	ARTICLE	IF	CITATIONS
199	Immunology of B7-H1 and Its Roles in Human Diseases. International Journal of Hematology, 2003, 78, 321-328.	1.6	34
200	B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex. Journal of Immunology, 2018, 201, 897-907.	0.8	34
201	New B7 Family Members with Positive and Negative Costimulatory Function. American Journal of Transplantation, 2004, 4, 8-14.	4.7	33
202	PD-1 Suppresses Protective Immunity to <i>Streptococcus pneumoniae</i> through a B Cellâ€œIntrinsic Mechanism. Journal of Immunology, 2015, 194, 2289-2299.	0.8	33
203	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology, 2021, 23, 1922-1935.	1.2	33
204	B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb. Cellular and Molecular Immunology, 2018, 15, 888-897.	10.5	32
205	Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity. Clinical Cancer Research, 2019, 25, 6180-6194.	7.0	32
206	Blockade of LIGHT/LTÎ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	8.2	32
207	Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends in Molecular Medicine, 2006, 12, 244-246.	6.7	30
208	Loss of B7-H1 Expression by Recipient Parenchymal Cells Leads to Expansion of Infiltrating Donor CD8+ T Cells and Persistence of Graft-Versus-Host Disease. Journal of Immunology, 2012, 188, 724-734.	0.8	30
209	Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells. Cancer Immunology Research, 2019, 7, 123-135.	3.4	30
210	B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. OncoImmunology, 2020, 9, 1684127.	4.6	30
211	Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1574-1579.	1.5	29
212	Structural insight into T cell coinhibition by PD-1H (VISTA). Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1648-1657.	7.1	29
213	Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage. Clinical Cancer Research, 2009, 15, 770-777.	7.0	28
214	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. Journal of Visualized Experiments, 2013, , .	0.3	28
215	Ligand Binding Sites of Inducible Costimulator and High Avidity Mutants with Improved Function. Journal of Experimental Medicine, 2002, 195, 1033-1041.	8.5	27
216	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology, 2016, 136, 994-1001.	0.7	27

#	ARTICLE	IF	CITATIONS
217	Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination. <i>Clinical Cancer Research</i> , 2009, 15, 1507-1509.	7.0	25
218	Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. <i>Cancer Research</i> , 2002, 62, 4413-8.	0.9	23
219	Cancer immunotherapy: are we there yet?. <i>Experimental Hematology and Oncology</i> , 2013, 2, 33.	5.0	22
220	CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert. <i>Clinical Cancer Research</i> , 2014, 20, 3-5.	7.0	21
221	Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8+ T cell responses during acute Friend retrovirus infection. <i>Retrovirology</i> , 2017, 14, 42.	2.0	20
222	An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion. <i>Bone Research</i> , 2021, 9, 47.	11.4	20
223	Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 203-214.	4.2	18
224	The B7 Homologues and their Receptors in Hematologic Malignancies. <i>European Journal of Haematology</i> , 2012, 88, 465-475.	2.2	17
225	Adaptive resistance: A tumor strategy to evade immune attack. <i>European Journal of Immunology</i> , 2013, 43, 576-579.	2.9	17
226	Effects of Specific Immunotherapy on the B7 Family of Costimulatory Molecules in Allergic Inflammation. <i>Journal of Immunology</i> , 2007, 178, 1931-1937.	0.8	16
227	CD137 ligand signaling enhances myelopoiesis during infections. <i>European Journal of Immunology</i> , 2013, 43, 1555-1567.	2.9	16
228	Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability. <i>Scientific Reports</i> , 2017, 7, 6086.	3.3	16
229	S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. <i>Oncotmunology</i> , 2018, 7, e1296996.	4.6	15
230	Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments. <i>Immunological Investigations</i> , 2006, 35, 395-418.	2.0	14
231	Leucocyte-associated immunoglobulin-like receptor-1 is an inhibitory regulator of contact hypersensitivity. <i>Immunology</i> , 2009, 128, 543-555.	4.4	14
232	Costimulation of α T cells by B7-H2, a B7-like molecule that binds ICOS. <i>Blood</i> , 2000, 96, 2808-2813.	1.4	14
233	CD137 Facilitates the Resolution of Acute DSS-Induced Colonic Inflammation in Mice. <i>PLoS ONE</i> , 2013, 8, e73277.	2.5	13
234	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.7	13

#	ARTICLE	IF	CITATIONS
235	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports, 2021, 11, 13482.	3.3	13
236	Costimulation-based immunotherapy for head and neck cancer. Current Treatment Options in Oncology, 2004, 5, 27-33.	3.0	12
237	CD28H expression identifies resident memory CD8 ⁺ T cells with less cytotoxicity in human peripheral tissues and cancers. OncoImmunology, 2019, 8, e1538440.	4.6	12
238	Costimulation of T-cell-mediated tumor immunity. Cancer Chemotherapy and Pharmacology, 1996, 38, S40.	2.3	11
239	Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Current Opinion in Immunology, 1999, 11, 219-222.	5.5	11
240	Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules. Molecular Biotechnology, 2002, 21, 259-264.	2.4	10
241	In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood, 2000, 95, 2346-2351.	1.4	10
242	Control of Autoimmune Diseases by the B7-CD28 Family Molecules. Current Pharmaceutical Design, 2004, 10, 121-128.	1.9	10
243	Dendritic cell-associated B7-H3 suppresses the production of autoantibodies and renal inflammation in a mouse model of systemic lupus erythematosus. Cell Death and Disease, 2019, 10, 393.	6.3	9
244	Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 150-159.	1.7	9
245	The CD8 ⁺ “PILR” interaction maintains CD8 ⁺ T cell quiescence. Science, 2022, 376, 996-1001.	12.6	9
246	Structural immunology of costimulatory and coinhibitory molecules. Science China Life Sciences, 2010, 53, 183-189.	4.9	8
247	B7-H4 Pathway in Islet Transplantation and β -Cell Replacement Therapies. Journal of Transplantation, 2011, 2011, 1-8.	0.5	8
248	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
249	The Many Sounds of T Lymphocyte Silence. Immunologic Research, 2005, 33, 135-148.	2.9	7
250	When immunotherapy meets surgery in non-small cell lung cancer. Cancer Cell, 2022, 40, 603-605.	16.8	7
251	T lymphocyte costimulatory molecules in host defense and immunologic diseases. Annals of Allergy, Asthma and Immunology, 2000, 85, 164-176.	1.0	6
252	Antibody gene therapy: Old wine in a new bottle. Nature Medicine, 2002, 8, 333-334.	30.7	6

#	ARTICLE	IF	CITATIONS
253	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2014, 20, 254-255.	2.0	6
254	Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-CELL tolerance. Frontiers in Bioscience - Landmark, 2002, 7, d853.	3.0	5
255	B7-H1 connection of innate and adaptive immunity against tumor dormancy. Blood, 2005, 105, 2242-2243.	1.4	4
256	Turning the Tide of Lymphocyte Costimulation. Journal of Immunology, 2009, 182, 2557-2558.	0.8	4
257	Overcoming T Cell Ignorance by Providing Costimulation. Advances in Experimental Medicine and Biology, 1998, , 159-165.	1.6	4
258	Mechanisms of GVL Against a Murine Blast Crisis CML.. Blood, 2006, 108, 191-191.	1.4	4
259	The role of B7-2 (CD86) in tumour immunity. Expert Opinion on Investigational Drugs, 1997, 6, 677-684.	4.1	3
260	Myeloid Cellsâ€™ Evasion of Melanoma Immunity. Journal of Investigative Dermatology, 2014, 134, 2675-2677.	0.7	3
261	Radiation-Free Anti-CD3-Conditioning Regimen Maintains Tissue Protection Mechanisms and Prevents GVHD: Role of Tissue Expression of B7H1. Blood, 2008, 112, 62-62.	1.4	3
262	Ablation of T cellâ€™associated PD-1H enhances functionality and promotes adoptive immunotherapy. JCI Insight, 2022, 7, .	5.0	3
263	Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules. , 2000, 45, 247-255.		2
264	The development and functions of CD4+ T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope. Cellular and Molecular Immunology, 2011, 8, 333-340.	10.5	2
265	Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab.. Journal of Clinical Oncology, 2012, 30, 2514-2514.	1.6	2
266	A new look at tumor immunology. Trends in Immunology, 1994, 15, 248.	7.5	1
267	Immunosuppressive Microenvironment in Head and Neck Cancer. , 2015, , .		1
268	Anti-B7-H4. , 2017, , 21-29.		1
269	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
270	Immunological Ignorance in Cancer. , 2004, , 87-99.		1

#	ARTICLE	IF	CITATIONS
271	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers.. Journal of Clinical Oncology, 2012, 30, 5506-5506.	1.6	1
272	Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?. Journal of Thoracic Oncology, 2022, 17, 592-595.	1.1	1
273	Immune Modulations. , 2005, , 475-490.		0
274	Anti-TOSO antibody treatment promotes T cell activation-induced cell death (AICD) in vitro and in vivo. Science Bulletin, 2014, 59, 1374-1385.	1.7	0
275	B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells. Oncoimmunology, 2018, 7, e1504156.	4.6	0
276	The Role of Leukemia Derived B7-H1 in Tumor-T-Cell Interactions in Humans.. Blood, 2005, 106, 4566-4566.	1.4	0
277	Interferon- γ and Tumor Necrosis Factor- α Induce An Immunoinhibitory Molecule, B7-H1, Via NF- κ B Activation in Blasts of Myelodysplastic Syndromes.. Blood, 2009, 114, 2766-2766.	1.4	0
278	Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy. Blood, 2010, 116, 422-422.	1.4	0
279	Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity. , 2012, , 251-266.		0
280	Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease. Blood, 2011, 118, 2974-2974.	1.4	0
281	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. , 2012, , 291-306.		0
282	B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior. Blood, 2011, 118, 474-474.	1.4	0
283	Anti-B7-H4. , 2013, , 1-9.		0
284	Host Tissue PD-1 Pathway Contribute To Murine Chronic Graft-Versus-Host Disease Via Th1+Th17+ Cells. Blood, 2013, 122, 3244-3244.	1.4	0
285	B7H1/B7.1 Interaction Alleviate Acute Cvhd in a PD-1 Dependent Manner. Blood, 2014, 124, 2423-2423.	1.4	0
286	CD137 in the Regulation of T Cell Response to Antigen. , 2006, , 83-96.		0
287	Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. , 2008, , 29-40.		0